SBIR-STTR Award

Developing Heparan Sulfate Glycan Array
Award last edited on: 9/24/2022

Sponsored Program
STTR
Awarding Agency
NIH : NIGMS
Total Award Amount
$2,708,473
Award Phase
2
Solicitation Topic Code
859
Principal Investigator
Guowei Su

Company Information

Glycan Therapeutics LLC (AKA: Glycan Therapeutics Corporation )

617 Hutton Street Suite 101
Raleigh, NC 27606
   (919) 977-1083
   info@glycantherapeutics.com
   www.glycantherapeutics.com

Research Institution

University of North Carolina

Phase I

Contract Number: 1R41GM123792-01A1
Start Date: 9/1/2017    Completed: 8/31/2019
Phase I year
2017
Phase I Amount
$149,901
Developing heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfate (HS) and proteins. HS is a highly sulfated polysaccharide displaying a wide range of biological functions. Glycan Therapeutics is a company specialized in HS related research products. In this proposal, an HS array technique will be constructed using both a microtiter plate format and a microarray format. The strength of the company is the capability of synthesizing structurally defined HS oligosaccharides using the chemoenzymatic method, allowing the synthesis of HS oligosaccharide in gram scale. This synthetic capability will ensure access to the oligosaccharide substrates at low cost and allows Glycan Therapeutics to have full control over the purity of the substrates. This unique strength will enable Glycan Therapeutics to produce high quality HS microtiter plates and HS micro-array chips at an affordable price. Aim 1 is designed to prepare HS microtiter plates based HS array. The major advantage of HS microtiter plate is that they are reusable and convenient. No additional equipment other than a microplate reader is needed. Furthermore, this method can be expanded to investigate the roles of HS in cell-based functional assays. Aim 2 is to prepare HS microarray technique. This technique will allow screening a very large number of HS oligosaccharides and proteins using very small amounts of carbohydrate and protein samples. The HS microarray technology will be readily integrated with existing carbohydrate-array methods in a centralized facility specialized in carbohydrate screening. In phase I studies, a library of 60 HS oligosaccharides will be affixed on a microtiter plate or on a microarray slide for biological screening. The HS microtiter plates or array slides will be tested thoroughly to ensure quality. In the phase II studies, the number of oligosaccharides on the microtiter plates and array slides will be expanded to 200 to fully represent the structures of HS isolated from natural sources. Success will lead to a convenient and reliable approach for improving research in glycosciences.

Public Health Relevance Statement:
Project Narrative Heparan sulfates are highly important polysaccharides that interact with different proteins to regulate human physiology. In this project, Glycan Therapeutics plans to develop an innovative tool to study the binding selectivity of heparan sulfate and proteins. The success of the project will advance glycosciences in the research community.

Project Terms:
Antibodies; Bacterial Infections; base; Binding; Biological; Biological Assay; Biological Process; Blood coagulation; Budgets; Carbohydrates; Cells; Communities; cost; cost effective; Custom; design; Embryonic Development; Ensure; Equipment; Extracellular Matrix; Heparitin Sulfate; high throughput screening; Human; Immobilization; improved; Inflammatory Response; innovation; interest; Label; Letters; Libraries; Licensing; Methods; Microarray Analysis; milligram; Monitor; new technology; North Carolina; Oligosaccharides; phase 1 study; phase 2 study; Physiological; Physiology; Play; Polysaccharides; Positioning Attribute; Preparation; Price; Process; Proteins; Reader; Research; Research Support; response; Role; Sampling; screening; Services; Ships; Slide; Small Business Technology Transfer Research; Source; Structure; Structure-Activity Relationship; success; Surface; System; Techniques; Technology; Testing; Therapeutic; Tissues; tool; United States National Institutes of Health; Universities; Unspecified or Sulfate Ion Sulfates; Validation; Viral

Phase II

Contract Number: 5R41GM123792-02
Start Date: 9/1/2017    Completed: 8/31/2019
Phase II year
2018
(last award dollars: 2021)
Phase II Amount
$2,558,572

Developing heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfate (HS) and proteins. HS is a highly sulfated polysaccharide displaying a wide range of biological functions. Glycan Therapeutics is a company specialized in HS related research products. In this proposal, an HS array technique will be constructed using both a microtiter plate format and a microarray format. The strength of the company is the capability of synthesizing structurally defined HS oligosaccharides using the chemoenzymatic method, allowing the synthesis of HS oligosaccharide in gram scale. This synthetic capability will ensure access to the oligosaccharide substrates at low cost and allows Glycan Therapeutics to have full control over the purity of the substrates. This unique strength will enable Glycan Therapeutics to produce high quality HS microtiter plates and HS micro-array chips at an affordable price. Aim 1 is designed to prepare HS microtiter plates based HS array. The major advantage of HS microtiter plate is that they are reusable and convenient. No additional equipment other than a microplate reader is needed. Furthermore, this method can be expanded to investigate the roles of HS in cell-based functional assays. Aim 2 is to prepare HS microarray technique. This technique will allow screening a very large number of HS oligosaccharides and proteins using very small amounts of carbohydrate and protein samples. The HS microarray technology will be readily integrated with existing carbohydrate-array methods in a centralized facility specialized in carbohydrate screening. In phase I studies, a library of 60 HS oligosaccharides will be affixed on a microtiter plate or on a microarray slide for biological screening. The HS microtiter plates or array slides will be tested thoroughly to ensure quality. In the phase II studies, the number of oligosaccharides on the microtiter plates and array slides will be expanded to 200 to fully represent the structures of HS isolated from natural sources. Success will lead to a convenient and reliable approach for improving research in glycosciences.

Thesaurus Terms:
Antibodies; Bacterial Infections; Base; Binding; Biological; Biological Assay; Biological Process; Blood Coagulation; Budgets; Carbohydrates; Cells; Communities; Cost; Cost Effective; Custom; Design; Embryonic Development; Ensure; Equipment; Extracellular Matrix; Heparitin Sulfate; High Throughput Screening; Human; Immobilization; Improved; Inflammatory Response; Innovation; Interest; Label; Letters; Libraries; Licensing; Methods; Microarray Analysis; Milligram; Monitor; New Technology; North Carolina; Oligosaccharides; Phase 1 Study; Phase 2 Study; Physiological; Physiology; Play; Polysaccharides; Positioning Attribute; Preparation; Price; Process; Proteins; Reader; Research; Research Support; Response; Role; Sampling; Screening; Services; Ships; Slide; Small Business Technology Transfer Research; Source; Structure; Structure-Activity Relationship; Success; Surface; System; Techniques; Technology; Testing; Therapeutic; Tissues; Tool; United States National Institutes Of Health; Universities; Unspecified Or Sulfate Ion Sulfates; Validation; Viral;